Furthermore, our results imply that the current cGAS or STING ligands under development for treating or serving as adjuvants in certain cancers38,39 will likely not work in tumor types defective in STAG2 and the cytosolic DNA-sensing pathway. This evidence concerns the gene CGAS and neoplasm.